Cargando…
MDM2-Dependent Rewiring of Metabolomic and Lipidomic Profiles in Dedifferentiated Liposarcoma Models
Dedifferentiated liposarcoma (DDLPS) is an aggressive mesenchymal cancer marked by amplification of MDM2, an inhibitor of the tumor suppressor TP53. DDLPS patients with higher MDM2 amplification have lower chemotherapy sensitivity and worse outcome than patients with lower MDM2 amplification. We hyp...
Autores principales: | Patt, Andrew, Demoret, Bryce, Stets, Colin, Bill, Kate-Lynn, Smith, Philip, Vijay, Anitha, Patterson, Andrew, Hays, John, Hoang, Mindy, Chen, James L., Mathé, Ewy A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7463633/ https://www.ncbi.nlm.nih.gov/pubmed/32759684 http://dx.doi.org/10.3390/cancers12082157 |
Ejemplares similares
-
Inhibition of histone deacetylase 2 reduces MDM2 expression and reduces tumor growth in dedifferentiated liposarcoma
por: Seligson, Nathan D., et al.
Publicado: (2019) -
Targeting the MDM2-p53 pathway in dedifferentiated liposarcoma
por: Traweek, Raymond S., et al.
Publicado: (2022) -
Intraperitoneal dedifferentiated liposarcoma showing MDM2 amplification: case report
por: Grifasi, Carlo, et al.
Publicado: (2013) -
Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas
por: Laroche-Clary, Audrey, et al.
Publicado: (2017) -
Cracking the riddle of dedifferentiated liposarcoma: is EV-MDM2 a key?
por: Casadei, Lucia, et al.
Publicado: (2020)